EcoDrugPlus

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSLDG00000008117
Gene Symbol: LOC111666673
3 Cross references
167 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSLDG00000017216
Gene Symbol: LOC111662428
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSSLDG00000011077
Gene Symbol: LOC111667910
3 Cross references
170 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSSLDG00000019500
Gene Symbol: LOC111645129
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSSLDG00000016780
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSSLDG00000018678
Gene Symbol: LOC111663044
2 Cross references
212 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSSLDG00000004750
Gene Symbol: LOC111656786
3 Cross references
182 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSSLDG00000022322
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSSLDG00000004537
Gene Symbol: PTGS2
3 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSSLDG00000000876
Gene Symbol: LOC111644199
3 Cross references
194 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSSLDG00000004189
Gene Symbol: PSMA1
3 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSSLDG00000013476
Gene Symbol: PSMA2
3 Cross references
268 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).